ArticleMolecular medicine reports2022

CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.

Linjin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.